The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.1M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 698K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

19 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery of Dual Inhibitors for Wild Type and D816V Mutant of c-KIT Kinase through Virtual and Biochemical Screening of Natural Products.EBI
Sejong University
Structure-based de novo design and synthesis of aminothiazole-based p38 MAP kinase inhibitors.EBI
Sejong University
Virtual screening and biochemical evaluation to identify new inhibitors of mammalian target of rapamycin (mTOR).EBI
Sejong University
Discovery of potent inhibitors of receptor protein tyrosine phosphatase sigma through the structure-based virtual screening.EBI
Sejong University
Discovery of MEK/PI3K dual inhibitor via structure-based virtual screening.EBI
Sejong University
Structure-based virtual screening approach to identify novel classes of PTP1B inhibitors.EBI
Sejong University
N-hydroxy-2-(naphthalene-2-ylsulfanyl)-acetamide, a novel hydroxamic acid-based inhibitor of aminopeptidase N and its anti-angiogenic activity.EBI
Sejong University
Structure-based virtual screening approach to the discovery of p38 MAP kinase inhibitors.EBI
Sejong University
Structure-based de novo design and biochemical evaluation of novel BRAF kinase inhibitors.EBI
Sejong University
Identification of novel BRAF kinase inhibitors with structure-based virtual screening.EBI
Sejong University
Structure-based virtual screening approach to the discovery of phosphoinositide 3-kinase alpha inhibitors.EBI
Sejong University
Structure-based virtual screening approach to the discovery of novel inhibitors of factor-inhibiting HIF-1: identification of new chelating groups for the active-site ferrous ion.EBI
Sejong University
Structure-based virtual screening approach to identify novel classes of Cdc25B phosphatase inhibitors.EBI
Sejong University
Structure-based de novo design and biochemical evaluation of novel Cdc25 phosphatase inhibitors.EBI
Sejong University
Identification of novel inhibitors of extracellular signal-regulated kinase 2 based on the structure-based virtual screening.EBI
Sejong University
Discovery of novel Cdc25 phosphatase inhibitors with micromolar activity based on the structure-based virtual screening.EBI
Sejong University
Discovery of novel PRL-3 inhibitors based on the structure-based virtual screening.EBI
Sejong University
Fluorinated NSC as a Cdc25 inhibitor.EBI
Sejong University
Application of Fragment-Based de Novo Design to the Discovery of Selective Picomolar Inhibitors of Glycogen Synthase Kinase-3 Beta.EBI
Sejong University